Search
for
Sort by
Research 30 of 1000+
- Cardiovascular Safety and Benefits of Testosterone Implant Therapy in Postmenopausal Women: Where Are We?
- LB1101 Evaluating the cardiovascular safety of low-dose oral minoxidil in patients with non-scarring alopecia: A retrospective cohort study
- CARDIOVASCULAR SAFETY OF LOW-DOSE ORAL MINOXIDIL FOR ANDROGENETIC ALOPECIA IN PATIENTS WITH HYPERTENSION OR ARRHYTHMIAS
- Cardiovascular Safety Signals of Oral Versus Topical Minoxidil in FAERS: A Disproportionality Analysis (Analytic Cohort 2012–2025)
- The Cardiovascular Safety of Dutasteride
- Efficacy and Cardiovascular Safety of Low-Dose Oral Minoxidil for Adult Androgenetic Alopecia and Female Pattern Hair Loss: A Structured Evidence Map and SWiM Narrative Synthesis
- Safety measures in high-risk patients with cardiovascular disease and elderly patients undergoing hair restoration surgery
- 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
- Anti-androgen therapy in polyendocrine metabolic ovary syndrome (PMOS, formerly PCOS): efficacy, safety, and phenotype-oriented clinical decision-making
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- The Safety of Testosterone Therapy in Women
- Safety of testosterone use in women
- Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- EFFICACY AND SAFETY OF LOW-DOSE ORAL MINOXIDIL IN THE TREATMENT OF ANDROGENETIC ALOPECIA – A LITERATURE REVIEW
- Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- The efficacy and safety of oral minoxidil greater than 5 mg daily in hair loss disorders
- A STUDY OF EFFICACY AND SAFETY OF ORAL MINOXIDIL IN MALE ANDROGENETIC ALOPECIA
- A Retrospective Study on the Safety of Systemic Minoxidil for Hair Loss in the Older Population
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Oral minoxidil treatment for hair loss: A review of efficacy and safety
- Prace poglądowe Folate supplementation in patients with psoriasis treated with methotrexate – effect on safety and efficacy
- Testosterone Therapy in Women: A Literature Review of Clinical Indications, Dosing, Routes of Administration, and Safety
- TERAPIA ORAL OU TÓPICA? REVISÃO INTEGRATIVA SOBRE O USO DE MINOXIDIL NA ALOPECIA ANDROGENÉTICA
- Safety of Topical Minoxidil Solution: A One-Year, Prospective, Observational Study
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark